Ozempic Injection, Solution
NDC Package 0169-4181-13

11-digit billing NDC: 00169418113 · Billing unit: ML · 3 ML per package

Package Information

Ozempic (semaglutide) injection is oZEMPIC is indicated:•as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.•to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease.•to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes mellitus and chronic kidney disease. This formulation utilizes a injection, solution delivery system. Marketed by Novo Nordisk Pharmaceutical Industries, Lp, this product is identified by NDC 0169-4181 and is authorized under FDA application NDA209637.

Identification & Billing

NDC Package Code
0169-4181-13
Package Description
1 SYRINGE, PLASTIC in 1 CARTON / 3 mL in 1 SYRINGE, PLASTIC (0169-4181-03)
Product Code
11-Digit Billing Format
00169418113
Billing Unit
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
Units Per Package
3 ML
RxNorm Crosswalk
  • RxCUI: 1991306 - semaglutide 2 MG in 1.5 ML Pen Injector, 0.25 or 0.5 MG Dose
  • RxCUI: 1991306 - 0.25 MG, 0.5 MG Dose 1.5 ML semaglutide 1.34 MG/ML Pen Injector
  • RxCUI: 1991306 - semaglutide 2 MG per 1.5 ML Pen Injector, 0.25 or 0.5 MG Dose
  • RxCUI: 1991311 - OZEMPIC 2 MG in 1.5 ML Pen Injector, 0.25 or 0.5 MG Dose
  • RxCUI: 1991311 - 0.25 MG, 0.5 MG Dose 1.5 ML semaglutide 1.34 MG/ML Pen Injector [Ozempic]

Clinical Specifications

Proprietary Name
Ozempic
Non-Proprietary Name
Semaglutide
Substance Name
Semaglutide
Dosage Form
Injection, Solution - A liquid preparation containing one or more drug substances dissolved in a suitable solvent or mixture of mutually miscible solvents that is suitable for injection.
Administration Route
Subcutaneous - Administration beneath the skin; hypodermic. Synonymous with the term SUBDERMAL.
Active Ingredient(s)
Usage Information
OZEMPIC is indicated:•as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.•to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease.•to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes mellitus and chronic kidney disease.

Regulatory & Marketing

Labeler Name
Novo Nordisk Pharmaceutical Industries, Lp
Product Type
Human Prescription Drug
FDA Application #
NDA209637
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
10-07-2022
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (0169-4181). Click a package code to view its specific billing and regulatory data.

1 SYRINGE, PLASTIC in 1 CARTON / 3 mL in 1 SYRINGE, PLASTIC (0169-4181-90)

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 0169-4181-13 identifies a specific commercial package of 1 syringe, plastic in 1 carton / 3 ml in 1 syringe, plastic (0169-4181-03) of Ozempic, a human prescription drug labeled by Novo Nordisk Pharmaceutical Industries, Lp. This injection, solution is formulated for subcutaneous use and contains semaglutide as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Novo Nordisk Pharmaceutical Industries, Lp on October 07, 2022. The current certification is valid through December 31, 2027.

How is this Novo Nordisk Pharmaceutical Industries, Lp product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 00169418113. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. There are 3 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (4-4-2)
0169-4181-13
11-Digit CMS (5-4-2)
00169-4181-13

Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.